Chapter 57: Ophthalmic Drugs

Beginning with fundamental ocular anatomy and physiology, the chapter emphasizes how the cornea, lens, aqueous humor, and retina function in vision and how disruption of these structures leads to disease. Glaucoma emerges as the primary clinical focus, with discussion of open-angle and angle-closure presentations and the pathophysiology of optic nerve damage from elevated intraocular pressure. Therapeutic approaches to reduce intraocular pressure utilize multiple drug classes with distinct mechanisms: cholinergic agents including pilocarpine and echothiophate promote aqueous humor drainage through miosis; sympathomimetic medications like apraclonidine and dipivefrin enhance outflow and suppress fluid production; beta-blockers such as timolol and betaxolol decrease aqueous humor formation; carbonic anhydrase inhibitors including dorzolamide reduce fluid production; osmotic agents like mannitol and glycerin provide rapid pressure relief in acute situations; and prostaglandin agonists such as latanoprost improve drainage but risk pigmentation changes in the iris. The chapter extends to antimicrobial therapy for ocular infections, covering aminoglycosides, macrolides, polypeptide antibiotics, fluoroquinolones, sulfonamides, antifungal agents, and antivirals. Anti-inflammatory management employs topical corticosteroids and nonsteroidal anti-inflammatory drugs for postoperative care and allergic conditions. Diagnostic and procedural applications include topical anesthetics, mydriatic and cycloplegic agents, and fluorescein. Additional coverage encompasses antihistamines, mast cell stabilizers, decongestants, and lubricating agents for dry eye disease. Nursing considerations emphasize baseline ocular assessment, monitoring for adverse effects including blurred vision and systemic absorption, patient instruction on proper eyedrop administration and contamination prevention, adherence strategies, and safety precautions for photosensitivity and anesthetized eyes.